Coastline Trust Co Sells 2,116 Shares of AbbVie Inc. $ABBV

Coastline Trust Co cut its stake in AbbVie Inc. (NYSE:ABBV) by 4.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,738 shares of the company’s stock after selling 2,116 shares during the quarter. AbbVie makes up approximately 1.1% of Coastline Trust Co’s investment portfolio, making the stock its 23rd largest holding. Coastline Trust Co’s holdings in AbbVie were worth $12,226,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter valued at about $30,000. Abound Financial LLC acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $32,000. Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie in the first quarter valued at approximately $34,000. Marquette Asset Management LLC increased its stake in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. Finally, Phillip James Consulting Co. acquired a new stake in AbbVie during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock traded down $2.26 during midday trading on Thursday, reaching $259.33. The company had a trading volume of 1,107,928 shares, compared to its average volume of 6,428,697. The company has a market capitalization of $458.18 billion, a price-to-earnings ratio of 73.22, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29. The stock has a 50 day moving average price of $257.73 and a 200-day moving average price of $234.11. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $269.39.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the company posted $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Canaccord Genuity Group upped their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Guggenheim raised their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $272.66.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Rinvoq produced encouraging long-term vitiligo data. Phase 3 Viti-Up-1 and Viti-Up-2 results showed that facial and total-body repigmentation continued to improve through week 76. Combination treatment with narrowband UV-B phototherapy also produced numerically higher responses, strengthening Rinvoq’s dermatology opportunity. AbbVie Presents Long-Term Rinvoq Data
• Positive Sentiment: Zumilokibart advanced toward Phase 3 development. All three Phase 2 dosing regimens met the primary endpoint in moderate-to-severe atopic dermatitis, significantly improving EASI-75 response rates versus placebo. AbbVie selected the mid-dose regimen, adding a potentially important immunology asset beyond Humira. Zumilokibart Phase 2 Results
• Positive Sentiment: AbbVie’s early metabolic pipeline showed progress. Phase 1 data for long-acting amylin analog ABBV-295 indicated favorable tolerability, meaningful weight reduction and an approximately 11- to 12-day half-life, supporting less-frequent dosing and planned Phase 2 testing. ABBV-295 Phase 1 Data
• Positive Sentiment: The FDA approved Juvmo, a once-daily Parkinson’s disease treatment, expanding AbbVie’s neuroscience portfolio and giving the company exposure to a potentially multibillion-dollar market. AbbVie also formed an AI-development partnership with Valkai, which could improve clinical-development efficiency. AbbVie Juvmo FDA Approval
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. Investors will look for updates on Skyrizi and Rinvoq growth, Humira-related pressure and full-year guidance. AbbVie Third-Quarter Earnings Call
• Negative Sentiment: Despite the strong pipeline news, analysts note that ABBV’s elevated valuation, Humira biosimilar erosion and competitive pressure in immunology could limit upside and increase sensitivity to future clinical or earnings disappointments. AbbVie Buy Hold or Sell Analysis

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.